144 related articles for article (PubMed ID: 1835621)
21. [Prognostic factors in IgG and micromolecular multiple myeloma. Retrospective analysis of 50 consecutive cases].
Pasqualetti P; Casale R; Colantonio D; Festuccia V; Di Lauro G; Natali G
Minerva Med; 1987 May; 78(9):603-8. PubMed ID: 3587727
[TBL] [Abstract][Full Text] [Related]
22. A staging system for multiple myeloma based on the morphology of myeloma cells.
Murakami H; Kawada T; Saitoh T; Uchiumi H; Moridaira K; Matsushima T; Tsukamoto N; Tamura J; Morita K; Sawamura M; Karasawa M; Miyawaki S; Shinonome S; Shimano S; Sato S; Ogawara H; Tsuchiya J
Eur J Haematol; 1999 Jan; 62(1):63-7. PubMed ID: 9918314
[TBL] [Abstract][Full Text] [Related]
23. [Long-term survival and prognostic factors in stage II-III multiple myeloma treated with conventional chemotherapy].
Pertuiset E; Chevret S; Lioté F; Delauche MC; Bardin T; Dryll A; Kuntz D
Ann Med Interne (Paris); 1992; 143(8):519-24. PubMed ID: 1303595
[TBL] [Abstract][Full Text] [Related]
24. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors affecting the survival of patients with multiple myeloma. A retrospective analysis of 86 patients.
Rapoport BL; Falkson HC; Falkson G
S Afr Med J; 1991 Jan; 79(2):65-7. PubMed ID: 1989088
[TBL] [Abstract][Full Text] [Related]
26. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors and classification in multiple myeloma.
San Miguel JF; Sànchez J; Gonzalez M
Br J Cancer; 1989 Jan; 59(1):113-8. PubMed ID: 2757917
[TBL] [Abstract][Full Text] [Related]
28. Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma.
Durie BG; Salmon SE; Moon TE
Blood; 1980 Mar; 55(3):364-72. PubMed ID: 7357075
[TBL] [Abstract][Full Text] [Related]
29. The Merlini, Waldenström, Jayakar staging system revisited.
Merlini G; Gobbi PG; Ascari E
Eur J Haematol Suppl; 1989; 51():105-10. PubMed ID: 2697581
[TBL] [Abstract][Full Text] [Related]
30. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
31. Determination of plasma cell secreting potential as an index of maturity of myelomatous cells and a strong prognostic factor.
Symeonidis A; Kouraklis-Symeonidis A; Grouzi E; Zolota V; Melachrinou M; Kourea K; Fragopanagou E; Giannakoulas N; Seimeni U; Tiniakou M; Matsouka P; Zoumbos N
Leuk Lymphoma; 2002 Aug; 43(8):1605-12. PubMed ID: 12400603
[TBL] [Abstract][Full Text] [Related]
32. Improvement of Durie & Salmon staging for multiple myeloma by adding platelet count as a stratifying variable: a multivariate regression analysis of 163 untreated patients.
Cavo M; Galieni P; Grimaldi M; Zuffa E; Bonelli MA; Gobbi M; Tura S
Eur J Haematol Suppl; 1989; 51():99-104. PubMed ID: 2697598
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors and therapeutic results in multiple myeloma.
Nagai M; Kitahara T; Minato K; Takenaka T; Konda C; Seki S; Shimoyama M
Jpn J Clin Oncol; 1985 Sep; 15(3):505-15. PubMed ID: 4057632
[TBL] [Abstract][Full Text] [Related]
34. Characterization of myeloma cells by means of labeling index, bone marrow histology, and serum beta 2-microglobulin.
Schambeck CM; Bartl R; Höchtlen-Vollmar W; Wick M; Lamerz R; Fateh-Moghadam A
Am J Clin Pathol; 1996 Jul; 106(1):64-8. PubMed ID: 8701935
[TBL] [Abstract][Full Text] [Related]
35. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
[TBL] [Abstract][Full Text] [Related]
36. Prognostic relevance of cellular morphology in multiple myeloma.
Fritz E; Ludwig H; Kundi M
Blood; 1984 May; 63(5):1072-9. PubMed ID: 6713092
[TBL] [Abstract][Full Text] [Related]
37. [Clinical features and survival of Chilean patients with multiple myeloma].
Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
Rev Med Chil; 2007 Sep; 135(9):1111-7. PubMed ID: 18064364
[TBL] [Abstract][Full Text] [Related]
38. Stage III multiple myeloma: clinical and prognostic value of spinal bone marrow MR imaging.
Lecouvet FE; Vande Berg BC; Michaux L; Malghem J; Maldague BE; Jamart J; Ferrant A; Michaux JL
Radiology; 1998 Dec; 209(3):653-60. PubMed ID: 9844655
[TBL] [Abstract][Full Text] [Related]
39. Prognostic variables and clinical staging in multiple myeloma.
Cavo M; Galieni P; Zuffa E; Baccarani M; Gobbi M; Tura S
Blood; 1989 Oct; 74(5):1774-80. PubMed ID: 2790201
[TBL] [Abstract][Full Text] [Related]
40. [Prognostic value of the ratio of bone marrow plasma cells in multiple myeloma].
Pasqualetti P; Colantonio D; Casale R
Minerva Med; 1990 Mar; 81(3):129-33. PubMed ID: 2320280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
